Since Merck & Co. v. Teva Pharmaceuticals, blocking patent arguments have arisen in the Federal Circuit primarily in the pharmaceutical patent context, and until now have largely been limited to undermining evidence of commercial success. But just like gremlins fed after midnight, this doctrine inevitably spawned unwanted offspring that are now wreaking havoc… Assuming that no one would ever develop a product that might infringe a patent is inconsistent with numerous Federal Circuit realities. It’s right up there with the Tooth Fairy (sorry, kids).
The post Expansion of the Blocking Patent Doctrine: Trading Logic for Gremlins appeared first on IPWatchdog.com | Patents & Patent Law.
Recent Posts
- USPTO Hiring Freeze Ends, Patent Examiners Wanted
- Judiciary Committee Votes Squires Through 20-2
- Disney and Universal Become Latest to Sue Midjourney Over Generative AI Service
- Stewart Says USPTO Wants Early Validity Challenges, Not Late IPRs
- Solutions for a Better Patent System | IPWatchdog Unleashed